Switch SWCH 深 滬
已收盤 12-05 16:00:00 美东时间
34.25
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 34.25
- 總市值 541.15万
- 52周最高 34.26
- 市盈率 靜 878.21
- 換手率 0.00%
- 52周最低 22.82
- 委 比 0.00%
- 總股本 0.00亿
- 歷史最高 34.26
- 量 比 0
- 振 幅 0.00%
- 歷史最低 5.6986
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多机甲世界游戏下载 热门机甲世界游戏精选
探索未来战技巅峰，畅游在机甲世界的游戏海洋！本文带你领略热门的机甲游戏精选，无论是硬核策略还是震撼视觉效果，一应俱全。立即下载，打造属于你的钢铁英雄传说，在虚拟...
08-09 10:28
估值近500亿！AI数据中心巨头Switch秘密递表，最早11月登陆美股
8月8日，据彭博社消息，知情人士透露，数据中心运营商Switch已秘密向美国证券交易委员会提交首次公开募股(IPO)申请，旨在借助投资者对人工智能(AI)主题的...
08-08 11:24
Data center operator Switch confidentially files for IPO - report
Data center operator Switch confidentially filed for a US initial public offering. A Switch listing could come as soon as November, according to a Bloomberg report on Friday, which cited people fami...
08-08 06:13
Nintendo Q1 profit tops estimates on software strength
Nintendo (NTDOY) shares rose about 9.2% after the Japanese gaming company reported first-quarter operating profit and revenue well ahead of analyst expectations, helped by strong software sales and a ...
08-07 01:15
Franchetti S.p.A. to Switch Specialist Operator on Euronext Growth Milan
An announcement from Franchetti S.P.A. ( ($IT:FCH) ) is now available. Franchet...
08-07 00:29
BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering
BlossomHill Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative small molecule medicines for cancer treatment, has priced its upsized initial public offering of 9.375 million shares at $16.00 per share, raising $150 million in gross proceeds. The shares will begin trading on August 7, 2026, under the ticker "BLSM," with the offering expected to close on August 10, 2026. J.P. Morgan, Leerink Partners, and Gugg...
08-07 00:07
存储巨头财报未达高预期 AI概念股遭遇新一轮抛售 | 今夜看点
①Meta推出首款AI智能体Muse Code的测试版； ②OpenAI要求美法官驳回苹果诉讼，称“窃取商业机密”指控“毫无依据”； ③亚马逊旗下Zoox将在美国拉斯维加斯启动付费自动驾驶出行服务。
08-06 20:45
受益于游戏需求强劲及美关税退款，任天堂营业利润狂飙151%
8月6日，日本游戏制造商任天堂（Nintendo）公告，公司二季度（4月至6月）运营利润飙升151%，达到14260亿日元（约合903.6亿元人民币），超过了分...
08-06 20:38
Oculis Reports Q2 2026 Financial Results and Provides Company Update
Oculis Holding AG reported Q2 2026 results, highlighting progress in its neuro-ophthalmology pivot with Privosegtor advancing in optic neuritis and potential expansion into acute MS relapses following positive FDA feedback. Licaminlimab's PREDICT-1 trial for dry eye disease is on track with over 45% patient enrollment. The company has $282.3 million in cash, providing runway into H2 2029. Upcoming milestones include R&D Day for Privosegtor and to...
08-06 20:05
